

**Form 51-102F3**  
**Material Change Report**

**Item 1 Name and Address of Company**

Biocure Technology Inc. (the “Company”)  
950-1130 West Pender Street  
Vancouver, B.C. V6E 4A4

**Item 2 Date of Material Change**

October 28, 2024

**Item 3 News Release**

A news release was disseminated on October 18, 2024 through the facilities of Stockwatch.

**Item 4 Summary of Material Change**

The Company’s board approved and authorized a consolidation of the Company’s issued and outstanding shares on a nine old for one new basis (the “Consolidation”).

The Consolidation was effected after the close of trading on October 28, 2024.

**Item 5 Full Description of Material Change**

On October 28, the Company completed the Consolidation.

As a result, the 94,000,537 shares currently outstanding were consolidated to 10,444,504 shares. No fractional shares were issued as a result of the Consolidation. Instead, all fractional shares were rounded down to the next whole share. The Company’s outstanding stock options and share purchase warrants were adjusted upon completion of the Consolidation on the same basis.

The Company did not change its name or seek a new stock trading symbol from the Exchange in connection with the Consolidation. The Company’s shares continue to trade under the symbol “CURE”. The new CUSIP for the post-Consolidation shares is 09075T206 and the new ISIN is CA09075T2065

**Item 6 Reliance on subsection 7.1(2) or (3) of National Instrument 51-102**

This Report is not being filed on a confidential basis in reliance on subsection 7.1(2) or (3) of National Instrument 51-102.

**Item 7 Omitted Information**

No information has been omitted on the basis that it is confidential information.

**Item 8****Executive Officer**

Konstantin Lichtenwald is knowledgeable about the material change and the Report and may be contacted (604) 609-7146.

**Item 9****Date of Report**

November 1, 2024